Company
Bionomics Ltd
ASX:BNO
Bionomics is a biopharmaceutical company dedicated to developing better treatments for central nervous system disorders such as anxiety, depression and Alzheimer's disease.
16 stories
Bionomics completes Phase 2 of MODULATE combination clinical trial for colorectal cancer
The MODULATE trial is evaluating new experimental approaches to immunotherapy treatment in colorectal cancer patients.
Bionomics initiates 7-day dosing pharmacokinetic study of BNC210 tablets
The company’s lead drug candidate BNC210 is a novel, proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine receptor.
Bionomics begins phase II clinical trial of drug for treating agitation
Bionomics will recruit about 40 elderly patients in specialist geriatric hospital wards across Australia.